Appointment of Vincent Lenaerts as new CEO

We are pleased to announce that we have appointed Vincent Lenaerts, PhD as the new Chief Executive Officer of Nanovista, effective immediately.

Dr. Lenaerts has over 25 years of experience in the pharmaceutical industry, including nanotechnologies and drug delivery, where he held various global executive positions in both small and large pharmaceutical companies. Asked about his appointment with Nanovista, Dr. Lenaerts said that “There is a real need for safer cancer surgeries resulting in complete removal of malignant tissues. For many patients, Nanovista’s technology could obviate the need to administer chemotherapy or radiotherapy.”

Dr. Lenaerts has also demonstrated a successful track record of leading the growth of early and late stage companies, leading the clinical and financing strategies for companies such as Apidel SA (Switzerland) and UCB (UK). Dr. Christine Allen, President and Co-founder of Nanovista said, “My co-founders and I are delighted to have Dr. Lenaerts join Nanovista as CEO. Vincent brings a depth and breadth of experience building successful companies. His leadership will help Nanovista realize the full potential of its technology platform.”

Dr. Lenaerts obtained his PhD in Pharmaceutical Sciences from University of Louvain, Belgium in 1984 and began his career as a Professor at the University of Montreal until 1991.